Use CBS for the clinical syndrome and CBD for the pathology
Modern clinicopathological criteria separate the bedside syndrome from the underlying pathology. A patient may have asymmetric rigidity, apraxia, dystonia, myoclonus or cortical sensory dysfunction that fits CBS without it being possible to prove CBD pathology during life. Conversely, pathologically confirmed CBD can present with other phenotypes. A German second opinion should therefore clarify how certain the clinical syndrome is and what alternative pathology remains possible.
Asymmetry and cortical motor dysfunction are important clues
CBS often combines an asymmetric movement disorder with higher-order cortical motor dysfunction. The neurological examination should document which limb is affected first and how movement, learned actions, sensation and involuntary movements have changed over time.
- Asymmetric limb rigidity or akinesia
- Limb dystonia or myoclonus
- Limb apraxia or loss of learned purposeful movement
- Cortical sensory dysfunction
- Alien-limb phenomena when present
- Speech, language, cognition and behavioral change
Differentiate CBS from Parkinson, PSP, MSA and focal structural disease
Heidelberg, Charité and Freiburg all place corticobasal disease within specialist atypical-Parkinson differential diagnosis. The clinical chronology matters because early falls and gaze abnormalities may suggest PSP, prominent early autonomic failure may favor MSA, and a more typical levodopa-responsive syndrome may suggest idiopathic Parkinson’s disease. Structural lesions and other neurological causes must also be excluded when the presentation is atypical.
MRI is central to structural review but is not a stand-alone pathology test
Brain MRI can support the pattern of neurodegeneration and help exclude stroke, tumor, hydrocephalus or other structural explanations. Original DICOM images should be sent for a second opinion when possible. MRI findings alone do not reliably prove that CBD is the underlying pathology of a CBS phenotype.
Functional imaging is selected according to diagnostic uncertainty
Freiburg describes dopaminergic and additional functional imaging such as FDG-PET or dopamine-receptor imaging to help distinguish idiopathic Parkinson’s disease from atypical syndromes and to improve classification among MSA, PSP and corticobasal degeneration. These tests are adjuncts rather than mandatory tests for every patient.
Medication is aimed at symptoms, not at curing CBS
Specialists may review levodopa or other medication according to the dominant motor symptoms, dystonia, myoclonus, pain, mood, sleep or other problems. Response to Parkinson medication can be limited in atypical syndromes, so treatment should be judged by documented functional benefit and adverse effects rather than continued automatically.
Botulinum toxin can be relevant for selected focal dystonia
When painful or function-limiting focal dystonia is a major component of the syndrome, a movement-disorder specialist may consider botulinum-toxin treatment. This is symptom management and does not alter the underlying neurodegenerative process.
Rehabilitation should address apraxia as well as weakness and balance
Physiotherapy and occupational therapy in CBS need to account for cortical motor-planning impairment, asymmetric limb dysfunction, falls and progressive loss of independence. Practical goals include safer transfers, mobility aids, prevention of contractures and caregiver strategies for tasks that become difficult because of apraxia rather than simple muscle weakness.
Speech, language, cognition and swallowing may need separate assessment
CBS/CBD can involve language, cognition, speech and swallowing. Speech-language therapy and neuropsychology can help characterize the phenotype and plan communication and safety strategies. Progressive choking, aspiration concern, dehydration or weight loss should be assessed promptly near home when unstable.
What to send for a German CBS second opinion
A useful record package shows the asymmetry, cortical signs and progression rather than only listing the label CBD.
- Neurology and movement-disorder reports
- Timeline of which limb or function was affected first
- Description of apraxia, dystonia, myoclonus, alien-limb or cortical sensory features
- Brain MRI reports plus original DICOM images
- DaTSCAN, FDG-PET, SPECT or other functional imaging if already performed
- Current and previous medication with dose, duration and response
- Neuropsychology, speech/language and swallowing reports if available
- Physiotherapy/occupational-therapy reports and current mobility aids
- A specific question: confirm CBS, review likely differential pathology, optimize symptoms or plan rehabilitation/supportive care
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Atypical Parkinson syndromes clinic — Heidelberg University Hospital ↗
- Movement Disorders — Charité – Universitätsmedizin Berlin ↗
- Parkinson and atypical Parkinson diagnostics — University Medical Center Freiburg ↗
- Consensus criteria for corticobasal degeneration — Neurology / PubMed Central ↗
- Corticobasal Degeneration — National Institute of Neurological Disorders and Stroke ↗